New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
18:05 EDTMNOVMedicNova announces publication of positive phase 2 clinical results
MediciNova announced the publication of positive Phase 2 clinical results in two asthma studies in the Journal of Asthma. The publication reports on two Phase 2a clinical trials conducted by MediciNova, MN-221-CL-004 and MN-221-CL-005, which assessed the safety, tolerability, and FEV1 improvements in mild-moderate and moderate-to-severe asthmatics, respectively. MN-221 is designed to treat acute exacerbations via intravenous infusion, bypassing constricted airways to deliver the drug directly to the lungs. Preclinical studies showed MN-221 to have a high affinity for the beta(2)-adrenergic receptor, found primarily in the lungs, and a much lower affinity for the beta(1)-adrenergic receptor found primarily in cardiac tissue. These studies showed no worrisome increase in heart rate when MN-221 was administered.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2014
19:02 EDTMNOVMedicNova receives feedback from FDA regarding study protocol for MN-001 trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use